John F. Crowley is a man on a mission. As the newly appointed President and CEO of the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology advocacy group, Crowley brings a unique blend of personal passion and professional expertise to his role.

Crowley’s journey into the world of biotech began in 1998 when two of his children, Megan and Patrick, were diagnosed with Pompe disease, a rare and often fatal genetic disorder. Determined to find a cure, Crowley left his position at Bristol Myers Squibb and co-founded Novazyme Pharmaceuticals, a biotech startup dedicated to developing a treatment for Pompe disease. His tireless efforts ultimately led to the development of a life-saving drug for his children and others afflicted with the disease.

In his previous role as CEO of Amicus Therapeutics from 2005 to 2022, Crowley continued to champion the development of treatments for rare diseases. His personal experience as a father fighting for his children’s lives has given him a deep understanding of the challenges faced by patients and their families, and a unwavering commitment to putting their needs first.

Now, as he takes the helm of BIO, Crowley brings his decades of biotech experience and passion to advocating for policies that foster innovation, support entrepreneurship, and prioritize patients. He believes strongly in the power of biotechnology to transform lives and views a robust biotech industry as essential for both public health and national security.

With his unique perspective as a biotech leader, father, and former U.S. Navy intelligence officer, John Crowley is poised to be a powerful voice for the biotechnology industry. His personal story of turning tragedy into triumph through biotech innovation serves as an inspiration, while his strategic vision charts a course for American biotech leadership in an increasingly competitive global landscape. As Crowley himself put it, “The strength of our biotechnology industry is a testament to our nation’s capability to protect and enhance the lives of its citizens and those around the globe.”

For a rare opportunity to hear directly from this biotech visionary, don’t miss the upcoming fireside chat on June 20th at 1pm at Fulton Labs in Chicago. IBIO President & CEO John Conrad will sit down with John Crowley for an in-depth discussion on his background as a successful biotech entrepreneur and his vision as the new CEO of BIO. This is a chance to gain insights from a leader who has not only transformed the biotech industry but also changed the lives of patients and families through his tireless dedication. Register for this inspiring event at Fulton Labs: 400 N Aberdeen St, Chicago.

This article was originally published on iBIO NewsBrief. Gain a head start on your day with iBIO NewsBrief. Subscribe to receive top industry headlines delivered straight to your inbox.